| Identification | Back Directory | [Name]
STX-0119 | [CAS]
851095-32-4 | [Synonyms]
STX-0119
4-Quinolinecarboxamide, N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-2-phenyl- | [Molecular Formula]
C22H14N4O3 | [MDL Number]
MFCD04462306 | [MOL File]
851095-32-4.mol | [Molecular Weight]
382.37 |
| Chemical Properties | Back Directory | [density ]
1.374±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO: soluble | [form ]
Solid | [pka]
9.26±0.70(Predicted) | [color ]
White to light yellow | [InChIKey]
MNPXTRXFUMGQLK-UHFFFAOYSA-N | [SMILES]
O=C(NC1=NN=C(C2=CC=CO2)O1)C3=CC(C4=CC=CC=C4)=NC5=C3C=CC=C5 |
| Hazard Information | Back Directory | [Uses]
N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide is a small molecular inhibitor of STAT3, a cancer therapeutic agent against Glioblastoma multiforme tumor cells, and a drug target. | [in vivo]
STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice[1].
The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration[1]. | Animal Model: | Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model[1] | | Dosage: | 160 mg/kg | | Administration: | Oral gavage, daily for 4 days | | Result: | Suppressed the growth of SCC-3 cells significantly on the fourth day. |
| [IC 50]
STAT3: 74 μM (IC50, STAT3 transcription) |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|